【摘要】 目的:了解晚期前列腺癌联合雄激素阻断治疗的长期生存率。方法:选取1993年1月~2000年1月初采用联合雄激素阻断治疗的59例前列腺腺癌患者,其中28.81%和45.76%为临床局部晚期(T3-4 N0M0期)和转移(TxNxM+期)病例,全部随访5年以上。结果:全组病例3、5、7年的总体生存率分别是79.36%、61.46%、49.15%,其中,临床局部晚期和转移者的5年生存率分别为80.77%和32.65%,而高分化腺癌和低分化腺癌的5年生存率分别为86.21%和30%(P<0.01)。另外,PSA>30μg/L时其长期生存率有明显下降趋势。结论:采用内分泌治疗的晚期前列腺癌,病理低分化、临床分期达T3 c-4NxMx或TxNxM+期及PSA>30μg/L均提示预后较差,晚期前列腺癌病例的治疗应综合多因素,选择个体化方案。更多还原

【Abstract】 Objective: To understand long-term survival rate after combined androgen blockade(CAB) in patients with advanced prostate cancer.Methods: A selected population of 59 patients with advanced prostate cancer were treated with CAB.(28.81)%(17/59) of patients had clinical locally advanced disease(stage T3-4N0M0),and(45.76)%(27/59) of patients had metastatic disease(stage TxNxM+).Overall,patients were followed for a median of 62(range 6-136) months.Results: Of the 59 patients with advanced prostate cancer,3-year,5-year and 7-year overall survival rates were(79.36)%,(61.46)% and(49.15)%,respectively.The 5-year survival rate were(80.77)% and 32.65% for clinical locally advanced disease and metastatic disease.Specifically,men with poorly differentiated prostate cancer had a 5-year survival of only 30% when compared with men with well-differentiated prostate disease who had a 5-year survival of(86.21)%.Conclusion: Based on these findings,men with poorly differentiated cancer,stage T3c-4NxMx or TxNxM+and PSA level above 30 μg/L had a high probability of dying from their advanced prostate cancer.Natl J Androl,2005,11(10):770-771,774更多还原